S2 Ep8: The FDA Decision for Pompe Disease Therapy cover art

S2 Ep8: The FDA Decision for Pompe Disease Therapy

S2 Ep8: The FDA Decision for Pompe Disease Therapy

Listen for free

View show details

About this listen

 The FDA is expected to announce the final decision for the dual therapy AT-GAA, which uses miglustat in combination with cipaglucosidase alfa for treating Pompe disease, an inherited and often times fatal disorder. Expert Barry Byrne discusses the characteristics of the condition and what this FDA decision will mean for treatment.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.